Corporate Communications:
Dr. Lise Hébert
(450) 680-4500
Toll free (877) 680-4500
If you need additional assistance or information regarding the company, please
send an Email to:
webinfo@neurochem.com.
December 5, 2001
- Annual General and Special Shareholders' Meeting
Neurochem reports significant progress
Neurochem Inc. (TSX : NRM) held its Second Annual General and Special Shareholders' Meeting
today reporting significant progress in its Clinical and R&D programs and announcing
important upcoming...
(learn more by clicking here)
November 15, 2001
- Neurochem announces first quarter results and selection as top 30 growth company by
Montreal Business Magazine
Neurochem Inc. (TSX : NRM) announced today its results for the first quarter ended September
30, 2001. The Company reported a net loss of $1,660,000 or ($ 0.09) per share for the quarter,
compared to a...
(learn more by clicking here)
November 13, 2001
- Neurochem's data show early inflammation response during amyloid deposition in
Alzheimer's Disease model
Presentation at 31st Society for Neuroscience Annual Meeting in San Diego
Neurochem Inc. (TSX : NRM) will present new data tomorrow November 14, at the 31st Society for
Neuroscience (SFN) Annual Meeting in San Diego (November 12-16, 2001). The presentation...
(learn more by clicking here)
November 9, 2001
- U.S. patent issued for Neurochem
New Patent for Epilepsy Program Expands on Company's Central Nervous System (CNS) Platform
Neurochem Inc. (TSX : NRM) announces the issuance of a patent in the U.S. No. 6,306,909
relating to the Company's Epilepsy program. The U.S. patent was issued to Neurochem's research
collaborators in...
(learn more by clicking here)
October 24, 2001
- Neurochem announces clinical advisory board for promising Alzheimer's therapeutic
Distinguished International Experts Help Advance Alzhemed™ Program
Neurochem Inc. (TSX : NRM) is pleased to announce today the appointment of an outstanding
group of clinical physicians and scientists to its Clinical Advisory Board (CAB) for
Alzhemed™, a lead drug...
(learn more by clicking here)
October 15, 2001
- Neurochem receives $1.4 Million grant from FDA and OMP designation in Europe for
Fibrillex™.
Orphan Drug Designation already granted in U.S.
Neurochem Inc. (TSX : NRM) announced today that it received a CDN$1.4 million grant from
the Food and Drug Administration (FDA) in the U.S. for a pivotal Phase II/III study of
Fibrillex™, which is...
(learn more by clicking here)
October 12, 2001
- Neurochem Inc. regains full ownership rights on drug molecules for Alzheimer's disease
Neurochem Inc. (TSX : NRM) announces an agreement with H.Lundbeck A/S ("Lundbeck")
pursuant to which Neurochem will regain the full ownership and control of its anti-amyloid drug...
(learn more by clicking here)
October 4, 2001
- Neurochem and SELECT Therapeutics Collaborate on Alzheimer's Vaccine
New Amyloid-Based Vaccine Approach to Prevent Dementia
Neurochem Inc. (TSX : NRM) and SELECT Therapeutics, Inc. (AMEX: XZL) today announced the
initiation of a collaboration program to advance a novel vaccine intended to prevent...
(learn more by clicking here)
September 27, 2001
- Neurochem Inc. Announces Year end Results
Important advances in clinical & drug development and new collaborations in place
Neurochem Inc. (TSX : NRM) announced today its results for the fiscal year ended June
30, 2001, indicating significant growth and progress in its clinical and drug
development as well as important new...
(learn more by clicking here)
July 19, 2001
- Nycomed Amersham Imaging and Neurochem collaborate to create Alzheimer's diagnostic
Neurochem Inc. (TSX : NRM) and Nycomed Amersham Imaging today announced that the two
companieshave agreed to collaborate on the creation...
(learn more by clicking here)
July 17, 2001
- Neurochem provides update on clinical treatment for secondary amyloidosis
Neurochem, Inc. (TSX: NRM) today announced positive clinical Phase I data for
Fibrillex™, its therapeutic in development for the treatment of
Secondary Amyloidosis...
(learn more by clicking here)
June 22, 2001
- Neurochem Honoured With Prestigious "Prix de l'Emergence" From The
"Fondation Armand-Frappier"
Neurochem Inc. (TSX : NRM) is pleased to announce it has received The Fondation Armand-Frappier
2001 Award in the "Emergence" category. This award was created to honour Quebec
life science...
(learn more by clicking here)
May 14, 2001
- Neurochem Announces Third Quarter 2001 Financial Results
Neurochem Inc. (TSX : NRM) today announced fiscal third quarter 2001 financial results
for the three-month period ended March 31, 2001.
(learn more by clicking here)
May 7, 2001
- Neurochem Inc. Wins Prestigious "Genesis Award 2001" From BIOQuebec
Neurochem Inc. (TSX : NRM) is pleased to announce it has won BIOQuebec's Genesis Award
2001 in the "Innovation" category. This award honours the Quebec life science
company that ...
(learn more by clicking here)
February 14, 2001
- Neurochem Announces Second Quarter Financial Results.
Neurochem Inc. (TSX : NRM) today announced second quarter 2001 financial results for the
three-month period ended December 31, 2000. The Company reported net income of $1,184,000 or
$0.06 per, ...
(learn more by clicking here)
February 13, 2001
- Neurochem Reports Key Findings on Role of Inflammation in Alzheimer's Disease.
Neurochem Inc. (TSX : NRM) announced the results of a study which examined the genetic
predisposition of inflammatory responses of brain cells to amyloid protein, a key
element of Alzheimer's Disease, ...
(learn more by clicking here)
January 18, 2001
- Neurochem receives approval to begin phase II/III clinical trial in U.K. for
Fibrillex™
Neurochem Inc. (TSX : NRM) has received approval from the Clinical Trials Unit of the
Medicines Control Agency in the United Kingdom for the initiation of a pivotal Phase II/III
clinical study for Fibrillex™, ...
(learn more by clicking here)
|
2008
Archives 2000
